Hoth Therapeutics (HOTH) Fundamental Analysis: Revenue, Earnings & Valuation

8.82 / 10

Outperform

Fundamentally the company rates Outperform with an 8.8/10 score. Key strengths include high interest coverage, PB‑ROE advantage, strong asset‑MV, revenue‑MV, rapid inventory turnover and robust YoY revenue growth. Weaknesses are a 100% current‑liabilities ratio and zero long‑term debt to working‑capital, dragging the score.

Analysis Checks(8/10)

Revenue-MV

Value-0.28

Score3/3

Weight39.04%

1M Return8.11%

Total operating revenue (YoY growth rate %)

Value78.03

Score2/3

Weight0.54%

1M Return0.13%

Inventory turnover ratio

Value47.95

Score2/3

Weight-4.45%

1M Return-1.18%

Current liabilities / Total liabilities (%)

Value100.00

Score0/3

Weight-16.50%

1M Return-4.96%

PB-ROE

Value1.24

Score3/3

Weight49.17%

1M Return9.18%

Long-term debt to working capital ratio (%)

Value0.00

Score0/3

Weight-16.96%

1M Return-4.75%

Interest coverage ratio (EBIT / Interest expense) (%)

Value15.64

Score2/3

Weight-4.53%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value92.19

Score2/3

Weight0.22%

1M Return0.05%

Cost of sales ratio (%)

Value70.31

Score2/3

Weight-4.28%

1M Return-1.13%

Asset-MV

Value-0.49

Score2/3

Weight57.74%

1M Return11.12%

Is HOTH undervalued or overvalued?

HOTH scores 8.82/10 on fundamentals and holds a Discounted valuation at present. Backed by its -191.40% ROE, 0.00% net margin, -0.71 P/E ratio, 1.45 P/B ratio, and 29.69% earnings growth, these metrics solidify its Outperform investment rating.